AU2020314625A1 - Ehrlichia vaccines and immunogenic compositions - Google Patents

Ehrlichia vaccines and immunogenic compositions Download PDF

Info

Publication number
AU2020314625A1
AU2020314625A1 AU2020314625A AU2020314625A AU2020314625A1 AU 2020314625 A1 AU2020314625 A1 AU 2020314625A1 AU 2020314625 A AU2020314625 A AU 2020314625A AU 2020314625 A AU2020314625 A AU 2020314625A AU 2020314625 A1 AU2020314625 A1 AU 2020314625A1
Authority
AU
Australia
Prior art keywords
immunogenic composition
seq
trp36
trp140
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020314625A
Other languages
English (en)
Inventor
Paul J. Dominowski
Suman MAHAN
Jere W. Mcbride
Jason J. MILLERSHIP
Duncan M. Mwangi
Sharath RAI
Sharon M. WAPPEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Zoetis Services LLC
Original Assignee
Research Development Foundation
Zoetis Services LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation, Zoetis Services LLC filed Critical Research Development Foundation
Publication of AU2020314625A1 publication Critical patent/AU2020314625A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1246—Rickettsiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2020314625A 2019-07-12 2020-07-13 Ehrlichia vaccines and immunogenic compositions Abandoned AU2020314625A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962873843P 2019-07-12 2019-07-12
US62/873,843 2019-07-12
US201962879762P 2019-07-29 2019-07-29
US62/879,762 2019-07-29
US202063049476P 2020-07-08 2020-07-08
US63/049,476 2020-07-08
PCT/US2020/041779 WO2021011456A1 (en) 2019-07-12 2020-07-13 Ehrlichia vaccines and immunogenic compositions

Publications (1)

Publication Number Publication Date
AU2020314625A1 true AU2020314625A1 (en) 2022-02-03

Family

ID=71948757

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020314625A Abandoned AU2020314625A1 (en) 2019-07-12 2020-07-13 Ehrlichia vaccines and immunogenic compositions

Country Status (11)

Country Link
US (1) US12624093B2 (cg-RX-API-DMAC7.html)
EP (1) EP3996741A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022540197A (cg-RX-API-DMAC7.html)
CN (1) CN114514238A (cg-RX-API-DMAC7.html)
AU (1) AU2020314625A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022000347A2 (cg-RX-API-DMAC7.html)
CA (1) CA3146842A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000086A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022000525A (cg-RX-API-DMAC7.html)
PH (1) PH12022550081A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021011456A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025118050A1 (pt) * 2023-12-04 2025-06-12 Laboratório Bio-Vet Ltda Antígeno vacinal quimérico com ação tríplice contra erliquiose, anaplasmose e babesiose canina, vetor de expressão, célula recombinante, composição vacinal, kit de diagnóstico, método de tratamento e uso de proteína quimérica

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043085A (en) * 1998-08-27 2000-03-28 Research Development Foundation Ehrlichia canis 120-kDa immunodominant antigenic protein and gene
MXPA05004804A (es) 2002-11-04 2005-12-05 Res Dev Foundation Antigenos de p153 y p156 para el inmunodiagnostico de erliquiosis canina y humana y usos de los mismos.
CA2555413C (en) 2004-02-25 2013-12-17 Research Development Foundation An immunoreactive 38-kda ferric binding protein of ehrlichia canis and uses thereof
US20050202046A1 (en) 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
US7910593B2 (en) 2004-04-09 2011-03-22 Chugai Seiyaku Kabushiki Kaisha Water-soluble prodrugs
US7842474B2 (en) * 2005-04-04 2010-11-30 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
EP3527582B1 (en) * 2005-04-04 2022-08-17 IDEXX Laboratories, Inc. Ehrlichia canis diva (differentiate infected from vaccinated animals)
US8591906B2 (en) * 2005-06-16 2013-11-26 Research Development Foundation Immunoreactive protein orthologs of Ehrlichia canis and E. chaffeensis
EP1790656A1 (en) 2005-11-25 2007-05-30 Nanokem S.A. Solution-phase synthesis of leuprolide
WO2008000070A1 (en) * 2006-06-27 2008-01-03 Wellington Laboratories Inc. Glycyrrhetinic acid derivatives
EP2064231B2 (en) 2006-08-31 2020-08-26 Research Development Foundation Immunoreactive glycoprotein gp19 of ehrlichia canis
CL2008001806A1 (es) 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
WO2009102509A2 (en) 2008-01-10 2009-08-20 Research Development Foundation Vaccines and diagnostics for the ehrlichioses
ES2569907T3 (es) 2008-06-27 2016-05-13 Zoetis Services Llc Composiciones adyuvantes novedosas
CA2796563C (en) 2009-04-28 2018-05-22 Research Development Foundation Immunoreactive ehrlichia p120/p140 epitopes and uses thereof
HRP20181039T1 (hr) * 2010-05-28 2018-08-24 Zoetis Belgium S.A. Cjepiva koja sadrže kolesterol i cpg kao jedine molekule koje nose adjuvans
EP2433646A1 (en) * 2010-09-22 2012-03-28 Intervet International BV Vaccine against Ehrlichia canis and associated methods
CA2874966C (en) * 2012-05-31 2020-06-09 Zoetis Services Llc Vaccination with canine respiratory coronavirus for protection against b. bronchiseptica infections
SI3542819T1 (sl) 2013-05-14 2021-11-30 Zoetis Services Llc Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide
KR20200039025A (ko) 2013-09-19 2020-04-14 조에티스 서비시즈 엘엘씨 유성 아쥬반트
MX2020011887A (es) 2018-05-07 2021-03-29 Res Found Dev Polipéptidos inmunorreactivos.
AU2019311181A1 (en) 2018-07-27 2021-02-18 Research Development Foundation Chimeric immunogenic polypeptides

Also Published As

Publication number Publication date
BR112022000347A2 (pt) 2022-04-12
CL2022000086A1 (es) 2022-09-30
JP2022540197A (ja) 2022-09-14
CN114514238A (zh) 2022-05-17
EP3996741A1 (en) 2022-05-18
WO2021011456A1 (en) 2021-01-21
MX2022000525A (es) 2022-04-20
CA3146842A1 (en) 2021-01-21
PH12022550081A1 (en) 2023-04-12
US20220356231A1 (en) 2022-11-10
US12624093B2 (en) 2026-05-12

Similar Documents

Publication Publication Date Title
KR100517028B1 (ko) 경피 면역용 조성물
JP4718778B2 (ja) ウエストナイルワクチン
US20220105170A1 (en) African swine fever vaccine
KR102393038B1 (ko) OspA의 돌연변이체 단편 및 이에 관련된 방법 및 용도
ES2744709T3 (es) Expresión de una proteína quimérica KSAC y procedimiento de producción de proteínas solubles a alta presión
CN106822883A (zh) 分枝杆菌抗原组合物
Pacífico et al. Immunization with Schistosoma mansoni 22.6 kDa antigen induces partial protection against experimental infection in a recombinant protein form but not as DNA vaccine
JP6505084B2 (ja) 免疫刺激性オリゴヌクレオチドを含む新規のワクチン組成物
JP2016521754A (ja) クロストリジウム・ディフィシル(c.difficile)に対して免疫する組成物及び方法
US12624093B2 (en) Ehrlichia vaccines and immunogenic compositions
RU2677347C2 (ru) Вакцина против клещей рода rhipicephalus
WO2012065263A1 (en) Immunogenic compositions
RU2824881C2 (ru) Вакцины против ehrlichia и иммуногенные композиции
Venceslau-Carvalho et al. Nano-multilamellar lipid vesicles loaded with a recombinant form of the chikungunya virus E2 protein improve the induction of virus-neutralizing antibodies
US11833197B2 (en) Immunotherapy of leishmaniasis
WO2012125567A2 (en) Vaccine formulation of mannose coated peptide particles
US20240376161A1 (en) Recombinant chimeric protein, use thereof, and composition
WO2023240278A2 (en) Uses of glycolipids as a vaccine adjuvant and methods thereof
Haensler Oil emulsions as vaccine adjuvants
WO2022241312A1 (en) Tick mouthpart antigens as effective anti-tick vaccines
AU2021325648A1 (en) Anti-coronavirus vaccines